News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,132 Results
Type
Article (46660)
Company Profile (295)
Press Release (671177)
Section
Business (209195)
Career Advice (2189)
Deals (36012)
Drug Delivery (113)
Drug Development (82321)
Employer Resources (191)
FDA (16330)
Job Trends (15235)
News (352495)
Policy (33212)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (10)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (10)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (8)
2024 Genetown Digital (5)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (7)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2735)
Academic (2)
Accelerated approval (2)
Adcomms (23)
Allergies (82)
Alliances (50924)
ALS (85)
Alzheimer's disease (1391)
Antibody-drug conjugate (ADC) (114)
Approvals (16326)
Artificial intelligence (248)
Autoimmune disease (13)
Automation (14)
Bankruptcy (365)
Best Places to Work (11826)
BIOSECURE Act (19)
Biosimilars (103)
Biotechnology (201)
Bladder cancer (57)
Brain cancer (24)
Breast cancer (248)
Cancer (2001)
Cardiovascular disease (159)
Career advice (1833)
Career pathing (32)
CAR-T (149)
Cell therapy (413)
Cervical cancer (19)
Clinical research (66403)
Collaboration (786)
Compensation (447)
Complete response letters (21)
COVID-19 (2660)
CRISPR (36)
C-suite (209)
Cystic fibrosis (99)
Data (1929)
Decentralized trials (2)
Denatured (29)
Depression (37)
Diabetes (249)
Diagnostics (6482)
Digital health (17)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (113)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (87)
Earnings (87007)
Editorial (34)
Employer branding (25)
Employer resources (161)
Events (115114)
Executive appointments (643)
FDA (17437)
Featured Employer (53)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (710)
Gene editing (99)
Generative AI (21)
Gene therapy (289)
GLP-1 (728)
Government (4531)
Grass and pollen (4)
Guidances (48)
Healthcare (19187)
Huntington's disease (24)
IgA nephropathy (23)
Immunology and inflammation (108)
Indications (26)
Infectious disease (2791)
Inflammatory bowel disease (136)
Inflation Reduction Act (10)
Influenza (46)
Intellectual property (85)
Interviews (345)
IPO (16694)
IRA (42)
Job creations (3840)
Job search strategy (1570)
Kidney cancer (9)
Labor market (37)
Layoffs (469)
Leadership (17)
Legal (8059)
Liver cancer (71)
Lung cancer (296)
Lymphoma (130)
Machine learning (2)
Management (62)
Manufacturing (275)
MASH (62)
Medical device (13471)
Medtech (13476)
Mergers & acquisitions (19785)
Metabolic disorders (652)
Multiple sclerosis (70)
NASH (22)
Neurodegenerative disease (80)
Neuropsychiatric disorders (24)
Neuroscience (1870)
NextGen: Class of 2025 (6717)
Non-profit (4646)
Northern California (2413)
Now hiring (38)
Obesity (358)
Opinion (220)
Ovarian cancer (74)
Pain (78)
Pancreatic cancer (77)
Parkinson's disease (134)
Partnered (20)
Patents (204)
Patient recruitment (95)
Peanut (48)
People (59049)
Pharmaceutical (71)
Pharmacy benefit managers (18)
Phase I (20679)
Phase II (29229)
Phase III (21790)
Pipeline (979)
Podcasts (61)
Policy (113)
Postmarket research (2643)
Preclinical (8975)
Press Release (72)
Prostate cancer (93)
Psychedelics (32)
Radiopharmaceuticals (250)
Rare diseases (359)
Real estate (6221)
Recruiting (72)
Regulatory (22567)
Reports (55)
Research institute (2473)
Resumes & cover letters (374)
Rett syndrome (3)
RNA editing (3)
RSV (39)
Schizophrenia (66)
Series A (127)
Series B (80)
Service/supplier (14)
Sickle cell disease (52)
Southern California (2084)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3774)
State (2)
Stomach cancer (14)
Supply chain (60)
The Weekly (29)
United States (21269)
Vaccines (683)
Venture capitalists (38)
Webinars (12)
Weight loss (243)
Women's health (35)
Worklife (16)
Date
Today (121)
Last 7 days (599)
Last 30 days (2555)
Last 365 days (34213)
2025 (7890)
2024 (35947)
2023 (40860)
2022 (51924)
2021 (56499)
2020 (54898)
2019 (47645)
2018 (35936)
2017 (33085)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (792)
Alabama (50)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (39380)
Australia (6478)
California (5516)
Canada (1863)
China (476)
Colorado (252)
Connecticut (257)
Delaware (125)
Europe (85471)
Florida (812)
Georgia (199)
Hawaii (1)
Idaho (58)
Illinois (506)
India (25)
Indiana (298)
Iowa (9)
Japan (141)
Kansas (102)
Kentucky (25)
Louisiana (8)
Maine (60)
Maryland (839)
Massachusetts (4168)
Michigan (226)
Minnesota (383)
Mississippi (2)
Missouri (76)
Montana (27)
Nebraska (25)
Nevada (57)
New Hampshire (64)
New Jersey (1580)
New Mexico (30)
New York (1588)
North Carolina (952)
North Dakota (8)
Northern California (2413)
Ohio (192)
Oklahoma (14)
Oregon (33)
Pennsylvania (1253)
Puerto Rico (9)
Rhode Island (26)
South America (1169)
South Carolina (18)
South Dakota (1)
Southern California (2084)
Tennessee (93)
Texas (826)
Utah (167)
Virginia (128)
Washington D.C. (62)
Washington State (516)
West Virginia (3)
Wisconsin (57)
718,132 Results for "dermavant sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Dermavant Sciences has received approval in Japan for tapinarof cream, 1% for the treatment of both adults with psoriasis and patients 12 years of age and older with atopic dermatitis.
June 25, 2024
·
5 min read
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
·
11 min read
Business
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
·
16 min read
Press Releases
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
·
16 min read
Biotech Beach
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
April 29, 2024
·
5 min read
Drug Development
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Dermavant Sciences announced that new ADORING data including treatment of patients with skin of color from Phase 3 trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis will be presented at the 2024 American Academy of Dermatology Annual Meeting, to be held from March 8-12 in San Diego, California.
March 1, 2024
·
6 min read
Drug Development
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
Dermavant Sciences today announced that the data from ADORING 1 and ADORING 2, two identical, double-blind, randomized, vehicle-controlled pivotal Phase 3 trials of VTAMA® (tapinarof) cream, 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology.
May 21, 2024
·
8 min read
Business
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.
October 13, 2023
·
6 min read
Business
Dermavant Appoints John Darden as New Head of Marketing
Dermavant Sciences today announced the appointment of John Darden as Vice President of Marketing. Darden brings more than 15 years of sales, marketing and market access experience in dermatology and immunology.
October 5, 2023
·
3 min read
1 of 71,814
Next
